最大肺复张开放肺通气策略在急性呼吸窘迫综合征中的应用(PHARLAP):一项II期多中心随机对照临床试验
PHARLAP是一项II期多中心随机对照试验,纳入中重度ARDS成人,比较最大肺复张联合滴定呼气末正压及进一步限制潮气量策略与对照「保护性」通气。计划入组340例,因ART试验发表后于2017年10月2日提前终止,实际随机115例(男性57%,平均年龄53.6岁)。28天时两组无呼吸机天数无差异(中位16天[IQR 0-21] vs 14.5天[IQR 0-21.5],P=0.95),死亡率(24.6% vs 26.8%,P=0.79)和气胸发生率(5.2% vs 10.7%,P=0.32)亦无差异。干预组新发低氧辅助治疗使用更少(中位较基线变化0[IQR 0-1] vs 1[IQR 0-1],P=0.004),但新发心律失常更多(29% vs 13%,P=0.03)。
要点
- 中重度ARDS成人中,最大肺复张策略28天无呼吸机天数与对照保护性通气无差异(中位16天 vs 14.5天,P=0.95)。
- 最大肺复张策略未降低28天死亡率(24.6% vs 26.8%,P=0.79),气胸发生率亦无差异(5.2% vs 10.7%,P=0.32)。
- 干预组新发低氧辅助治疗(吸入一氧化氮、体外膜氧合、俯卧位)使用更少(中位变化0 vs 1,P=0.004)。
- 干预组新发心律失常发生率更高(29% vs 13%,P=0.03)。
- 该试验因ART试验发表后提前终止,实际随机115例,低于计划的340例。
适用人群与场景
- 成人中重度急性呼吸窘迫综合征患者。
处置流程与药物剂量
- 干预组接受最大肺复张、滴定的呼气末正压及进一步限制潮气量。
- 对照组接受「保护性」通气。
研究设计与关键结果
- II期多中心随机对照试验,计划入组340例,因ART试验发表后于2017年10月2日提前终止,实际随机115例(男性57%,平均年龄53.6岁)。
- 主要终点28天无呼吸机天数:最大肺复张组中位16天(IQR 0-21,n=57)vs 对照组14.5天(IQR 0-21.5,n=56),P=0.95。
- 死亡率:最大肺复张组24.6%(14/56)vs 对照组26.8%(15/56),P=0.79。
- 气胸发生率:最大肺复张组5.2%(3/57)vs 对照组10.7%(6/56),P=0.32。
- 新发低氧辅助治疗(如吸入一氧化氮、体外膜氧合、俯卧位)使用:最大肺复张组中位较基线变化0(IQR 0-1)vs 对照组1(IQR 0-1),P=0.004。
- 新发心律失常:最大肺复张组29%(17例)vs 对照组13%(7例),P=0.03。
证据类型、等级与局限
- 证据类型:II期多中心随机对照试验。
- 局限:因ART试验发表后提前终止,实际随机115例,低于计划的340例;原文未报告其他局限性。
对床旁实践的改变
- 在中重度ARDS成人中,最大肺复张策略未减少28天无呼吸机天数或死亡率,且与新发心律失常增加相关,但低氧辅助治疗使用更少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Open lung ventilation strategies have been recommended in patients with acute respiratory distress syndrome (ARDS).Objectives: To determine whether a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS.Methods: A phase II, multicenter randomized controlled trial in adults with moderate to severe ARDS. Patients received maximal lung recruitment, titrated positive end expiratory pressure and further Vt limitation, or control "protective" ventilation.Measurements and Main Results: The primary outcome was ventilator-free days at Day 28. Secondary outcomes included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay. Enrollment halted October 2, 2017, after publication of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a planned 340 patients had been randomized (57% male; mean age, 53.6 yr). At 28 days after randomization, there was no difference between the maximal lung recruitment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range (IQR), 0-21 d], n = 57, vs. 14.5 d [IQR, 0-21.5 d], n = 56; P = 0.95), mortality (24.6% [n = 14/56] vs. 26.8% [n = 15/56]; P = 0.79), or the rate of barotrauma (5.2% [n = 3/57] vs. 10.7% [n = 6/56]; P = 0.32). However, the intervention group showed reduced use of new hypoxemic adjuvant therapies (i.e., inhaled nitric oxide, extracorporeal membrane oxygenation, prone; median change from baseline 0 [IQR, 0-1] vs. 1 [IQR, 0-1]; P = 0.004) and increased rates of new cardiac arrhythmia (n = 17 [29%] vs. n = 7 [13%]; P = 0.03).Conclusions: Compared with control ventilation, maximal lung recruitment did not reduce the duration of ventilation-free days or mortality and was associated with increased cardiovascular adverse events but lower use of hypoxemic adjuvant therapies.Clinical trial registered with www.clinicaltrials.gov (NCT01667146).
参考来源
- Hodgson CL, Cooper DJ, Arabi Y, et al. Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP). A Phase II, Multicenter Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019. PMID: 31356105. doi:10.1164/rccm.201901-0109OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。